Widely used as a cytotoxic payload in antibody-drug conjugates (ADCs), enabling targeted delivery to cancer cells. Its high potency disrupts microtubule dynamics, leading to cell cycle arrest and apoptosis. Due to its mechanism, it is effective in low concentrations when linked to monoclonal antibodies that recognize tumor-specific antigens. This targeted approach minimizes damage to healthy tissues and enhances therapeutic efficacy in cancers such as lymphoma, leukemia, and solid tumors. Also employed in research settings to develop new conjugates and evaluate targeting strategies in oncology.